Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
272 hedge funds and large institutions have $3.91B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2019 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 101 increasing their positions, 84 reducing their positions, and 66 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 84
8% less funds holding
Funds holding: 297 → 272 (-25)
10% less capital invested
Capital invested by funds: $4.36B → $3.91B (-$449M)
26% less call options, than puts
Call options by funds: $11.5M | Put options by funds: $15.6M
32% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 66
40% less funds holding in top 10
Funds holding in top 10: 10 → 6 (-4)
Top Buyers
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$54.7M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$40.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.5M |
| 4 |
Millennium Management
New York
|
+$22.9M |
| 5 |
Renaissance Technologies
New York
|
+$22.7M |
Top Sellers
HZNP Hedge Fund Activity: Q2 2019 in Review
272 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q2 2019, worth a combined $3.91B — down 10% from $4.36B a quarter earlier.
Sellers outnumbered buyers: 66 funds closed out of HZNP and 45 opened new positions — a net loss of 21 holders — while 84 trimmed existing stakes and 101 added.
The largest buyer was Ameriprise, adding an estimated $54.7M. The largest seller was Scopia Capital Management, cutting an estimated $98.2M.
- 272 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q2 2019, down from 297 in Q1 2019.
- Funds reported $3.91B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q2 2019, down 10% quarter-over-quarter.
- 45 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q2 2019 and 66 closed out, a net change of -21 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q2 2019 was Ameriprise, an estimated $54.7M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q2 2019 was Scopia Capital Management, an estimated $98.2M sold.
Based on aggregated 13F filings for Q2 2019.